Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ODE V Deputy Bull To Step In "As Needed" For Novartis-Bound DeLap

This article was originally published in The Tan Sheet

Executive Summary

FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD is serving as the office's acting director in areas in which departing Director Robert DeLap, MD/PhD, has potential conflicts of interest.

You may also be interested in...

Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA

Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.


Jonca Bull, MD, appointed deputy director, Office of Drug Evaluation V, FDA announces June 22. Bull will move to the new position starting July 30, reporting to ODE V Director Robert DeLap, MD/PhD. Debra Bowen, MD, left the position early this year to join McNeil Consumer Healthcare as VP-clinical research (1"The Tan Sheet" Jan. 3, p. 13). Currently acting director of the Office of Women's Health, Bull previously worked in the Office of the Commissioner as a special assistant and medical advisor to the deputy commissioner for operations. Bull joined FDA in 1994

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts